Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • MPSC Cancels Drug Inspector Recruitment After Probe Finds Question Paper Leak Benefit
    26 August 2026

    MPSC Cancels Drug Inspector Recruitment After Probe Finds Question Paper Leak Benefit

    The Maharashtra Public Service Commission (MPSC) has cancelled the recruitment process for Drug Inspector, Group-B posts under the Food and Drug Administration Department, citing concerns over the integrity of the screening examination.

    The recruitment advertisement, No. 116/2025, was issued on July 29, 2025. The screening examination was conducted offline on March 22, 2026, at examination centres located in six divisional headquarters across Maharashtra. The result was declared on June 12, 2026, with 506 candidates qualifying for interviews.

  • 24 August 2026
    USFDA Inspection at Aurobindo Pharma’s Lannett Facility Concludes With Four Observations

    A routine inspection by the United States Food and Drug Administration (US FDA) at Lannett Company LLC, a wholly owned step-down subsidiary of Aurobindo Pharma USA, Inc., has concluded with four observations.

    The inspection was conducted at Lannett Company’s manufacturing facility in Seymour, Indiana, USA, from August 17 to August 21, 2026. According to the company’s regulatory filing, the inspection was carried out as part of the US FDA’s routine inspection process.

  • 24 August 2026
    Robot-assisted surgery shows clinical advantages over laparoscopic surgery for gastric cancer
    Surgery remains the primary curative treatment for gastric cancer, with laparoscopic gastrectomy (LG) established as a standard minimally invasive approach. While LG offers faster recovery than open surgery, it remains technically demanding because surgeons must operate within a confined space using rigid instruments that can amplify hand tremors.
  • 24 August 2026
    CDSCO Flags 239 Drug Samples as Not of Standard Quality in July 2026 Alert

    The Central Drugs Standard Control Organization (CDSCO) has released its July 2026 Not of Standard Quality (NSQ) drug alert, listing a large number of medicine samples that failed to meet specified quality standards during testing by state and CDSCO laboratories.

  • 22 August 2026
    PCI Unveils Four Major Initiatives to Transform Pharmacy Education, Research and Career Opportunities

    The Pharmacy Council of India (PCI) has introduced four major initiatives aimed at strengthening pharmacy education, research and professional development in India. The initiatives were unveiled at CAPSULE 4.0 and include the new M.Pharm (Medical Devices) programme, Research Promotion Scheme (RPS), Doctoral Fellowship Scheme (PDFS) and Pharmacy Awards.

  • 21 August 2026
    TDB Backs Vadodara Startup OrthoGraft to Commercialize Advanced Biological Dressings for Difficult Wounds
    The Technology Development Board (TDB), under the Department of Science & Technology (DST), Government of India, has extended financial assistance to Vadodara-based medical device startup OrthoGraft Pvt. Ltd. to establish a production facility for advanced tissue-derived biological dressings aimed at wound-care applications
  • 20 August 2026
    A smart cancer drug developed by India, could replace chemotherapy

    New ‘Smart’ Cancer Drug Targets Tumor Cells While Sparing Healthy Tissue. Scientists in India have developed a promising experimental cancer drug designed to activate mainly inside cancer cells, potentially offering a more selective approach than conventional chemotherapy.

  • 20 August 2026
    FDA Approves Second Treatment for Rare “Stone Man” Disease

    The U.S. Food and Drug Administration (FDA) has approved Pasatru (garetosmab-grts) as a treatment for adults with fibrodysplasia ossificans progressiva (FOP), an extremely rare genetic disorder in which muscles, tendons and ligaments can gradually turn into bone. The approval makes Pasatru the second FDA-approved treatment for FOP, providing another therapeutic option for people affected by this debilitating condition.

  • 18 August 2026
    USFDA Classifies Aurobindo Pharma’s Raleigh Facility as VAI; Inspection Closed
    Aurobindo Pharma Limited has announced that the United States Food and Drug Administration (USFDA) has classified its Raleigh plant in North Carolina, USA, as Voluntary Action Indicated (VAI) following an inspection conducted at the facility in 2025. The Raleigh plant is owned by Aurolife Pharma LLC, a wholly owned step-down subsidiary of Aurobindo Pharma Limited, and is established for the manufacturing of inhalers, dermatology and transdermal products.
  • 18 August 2026
    FDA Issues Warning Letter to Dabur India Over Major CGMP, Data Integrity and Validation Deficiencies

    The U.S. Food and Drug Administration (FDA) has issued a warning letter to Dabur India Limited following an inspection of the company’s drug manufacturing facility in Saily, Silvassa, Dadra and Nagar Haveli and Daman and Diu, India. The inspection, conducted from January 12 to 16, 2026, identified significant violations of Current Good Manufacturing Practice (CGMP) requirements for finished pharmaceuticals.

Subscribe to Pharma News